Abstract: New chalcones derived from coumarines were synthesized and tested as CDC25 phosphatase inhibitors. Molecular modeling of these new compounds was also presented in aim to study the mode of compounds orientation within CDC25 A and B. The reversibility of compounds 3, 4 and 5 was confirmed by application of MALDI-TOFMS technique.
Introduction
CDC25 (Cell Division Cycle) is dual specificity phosphatase that play critical role in the division of eukaryotic cells. Up to date, three CDC25 isoforms were identified: A, B and C [1] [2] [3] [4] . They dephosphorylate CDK/cyclin protein complexes which are key regulator of cell division. Noteworthy,CDC25B is needed for checkpoint recovery to repair DNA before mitosis 3, 5 . CDC25A and CDC25B are overexpressed in many different human cancers: (e.g.: breast cancer: 70% and 57%, colorectal cancer: 47-53% esophageal cancer: 46-66% and 48-79% respectively) 1 . Consequently, they appear as potential target in cancer therapy. Wide range of different scaffolds has been reported as CDC25 phosphatase inhibitors including quinoids, dysidiolide and large collection of miscellaneous structures 6, 7 . Chalcones have numerous biological activities containing antihypertensive, antifungal, anticonvulsant, antiviral, antioxidant, anti-inflammatory, antimalarial, anti-HIV, antiprotozoal, antimicrobial, antifilarial, 8, 9 they also proved their antitumor activities through their action against many molecular targets 10 . The substituted chalcones in position 4 of ring (B) was even reported as CDC25 inhibitors with considerable activity (Figure 1 ) 11 .Coumarines are well known as anticancer 12 active compounds with many different mechanisms like kinase inhibitors, apoptosis induction, angiogenetic inhibition, HSP90 inhibitors, telomerase inhibitor and antimitotic. 13 Some coumarines have anticoagulant and cardiovascular properties (dicoumarol and warfarin) others have antibiotic activities as novobiocin and clorobiocin which are naturally occurring.
14 Geiparvarin is another example of coumarine with dual activities: MAO-B inhibitory and antitumor. 15 Coumarine has been combined with different pharmacophores, and showed antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. 16 Some of them, hybridized with quinones 17, 18 or dimerized thanks to a disulfide bond of various lengths (Figure 1) 19 are particularly active.
Figure 1. Examples of substituted and coumarines based chalcones inhibitors of CDC25s
Synergistically, coumarine and chalcones combined structure appeared as promising anticancer molecules. They showed their abilities against number of human cancer cell lines, 20 therefore, series of novel chalcones derived from coumarine were synthesized by aldol condensation. The obtained compounds were investigated by docking simulation and then evaluated in vitro on CDC25A and B enzymes.
Results and Discussion
Chemistry All compounds were synthesized by well-known base-catalyzed aldol condensation 21 between 3-acetyl coumarines and cinnamaldehyde. Previously, in our laboratory, substituted 3-acetyl coumarines were prepared starting from salicylaldehyde 22 The electrophilic substitution: Cl and Br on position 6 of the coumarine part led to inhibit CDC25A in higher extent than methoxy substituted analogue. The order of activity of these compounds was 4>3>2. This order was inversed in the case of CDC25B. Introduction of methoxy group on the phenyl moiety increased the activity of compound 4 toward CDC25B but it diminished with CDC25A (from 35.95% to 7.34%). Furthermore, comparing the activities of compounds 1, 6 and 7; it showed that the methoxy group substitution on the phenyl ring increased the activity against both isoforms. The substitution on position 7 of coumarine with N, N-diethylamino group (compound 5) increased the inhibitory activity on CDC25A: 40.64±0.92% and CDC25B: 54.94±1.13%). This compound was finally the most potent candidate among all tested structures (Table 1) .
MALDI-TOFMS Matrix-assisted laser desorption/ionizationtime-of-flight mass spectrometry (MALDI-TOFMS) was applied to check if the synthesized structures may be a candidate to CDC25 inhibition. In case of inhibition, the applied procedure is also able to inform about its reversibility or irreversibility. 28 Compounds with the highest values in biological analysis as inhibitor (3, 4 and 5) gave a positive results in MALDI-TOFMS Their protonated molecular ion directly appeared in the mass spectrum meaning that they behaves as reversible inhibitors as described by Sibille et al. 29 and Bana et al. 17 . 
Molecular modelling
The molecular surface scanning of CDC25B reveals that its 3D structure exhibits a large groove just close to active cysteine 30 . Thus, this site called swimming pool also appears as an interesting target for inhibiting CDC25 by the binding of small molecules. 31 Hence, the binding inside this catalytic site cannot only be taken into account as a dependable mode of inhibition. We suggested designing of chalcones derived from coumarine and investigating the designed products by docking simulation to test the mode of orientation of each moiety in relation to active and inhibitory sites. Possibility of formyl pyranone ring to surrogate the phosphate group of the native substrate was presumed 6 .
The surface structure of the CDC25B catalytic domain (1QB0) 32 , indicated that the distance between the shallow active site and the large groove is ~ 7.3 Å. This distance must correspond to the linker length between the position 3 of the coumarine and the position 1 of the ring (B) of the chalcone-like moiety for inhibitor in 3D model. Using CDC25B as key model, we found that conjugating ketone-diene chain (n=2) provided a better linker length than a single double bond (n=1) for our approach. Coumarine was one of the counterparts of choice while the other was substituted aromatic ring, and they were intended to be hybridized. The docking study was achieved using AUTODOCK Vina 33 . We assumed that the coumarine compound is able to bind the cysteine of the catalytic site of CDC25B. Our docking study showed that, for the half of the structures tested, the coumarine part rather fitted inside the swimming pool of CDC25B, while the chalcone part entered the active site. This is observed for compounds 1, 4, 5 ( Figure 3 ) and 6 blocked whereas it is the contrary for compounds 2, 3, 7 and 8.
The docking with CDC25A was more challenging as the catalytic cysteine is located inside very shallow groove, with a very small cavity appearing unsuitable for fitting neither coumarine nor phenyl moiety of the compounds series. The docking results showed that the most of molecular poses are oriented in a way that the coumarine was toward the catalytic cysteine (cys430) which complying with phosphates group simulation assumption (1, 2, 3 (Figure 4), 4, 5, 6 ). (Table 1) .
This orientations similar to phosphate cradling model of the native substrate 34 . Compounds 7 and 8 had their binding mode in the opposite direction. Docking could not give the explanation of the inhibitory activity 29, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] , so it was necessary to synthesize these molecules and evaluated their biological activities with CDC25A and B then verification of their reversibility.
The CDC25s have two interesting sites: the active site and the swimming pool which can play an important role, so it would be efficient if both of them are tested in same time.
It has been suggested that the hybrid structure may be more efficient at inhibiting CDC25s. Indeed, the first moiety of the inhibitor could fit the binding pocket (i.e. the swimming pool) while the other part could bind to the active cysteine 48 .
Conclusion
The antitumor characteristics of both coumarine and chalcones inspired our approach to design hybrid structures could block both grooves of the protein (active and inhibitory) highlighting the lack of toxicity in the same time.
Several chalcones derived from coumarine were synthesized, the binding modes of them were tested by molecular modelling simulation, the probability of phosphate surrogating by coumarine ring has been shown by certain derivatives. Biological evaluation revealed some activity of the compounds. N, N-diethylamino substitution on position 7 of coumarine (compound 5) increasing the inhibitory activity on both isoforms of CDC25. The derivatives proved to perform reversible inhibition by MALDI-TOF analysis (compounds 3, 4 and 5). The designed scaffold could be considered as a basis of further lead optimization in order to obtain better inhibition.
Experimental Section
Chemistry All solvents were used as purchased unless otherwise noted. Melting points were determined on a Buchi 530 digital melting point apparatus.
1 H and 13 C NMR spectra were recorded at 400 MHz and 100 MHz, respectively, using Me 4 Si as the internal standard. Hydrogen coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m). High resolution mass spectra were measured using a MicroTof-Q98 instrument in ESI mode. Column chromatography was performed using silica gel (60M, 0.04-0.063 mm). Thin layer chromatography (TLC) was performed using silica gel plates (POLYGRAM SIL G/UV 254 , 0,20mm). For the visualization, TLC plates were placed under UV light.
General procedure for synthesis of compounds 1 to 8
In round bottom flask, 1.1 mmole of cinnamaldehydes and 1 mmole of substituted 3-acetyl coumarine were mixed in ethanol, and stirred under reflux till dissolving of coumarine derivatives. Afterward, 5% mole of piperidine was added and the reaction retained under reflux for 24 h. When the reaction completed, the solution allowed to be cooled, and the product started to precipitate. The obtained solid was filtered and recrystallized using ethanol. Oxo-5-phenyl-2Z, 4Z-pentadien-1-yl) 
3-(1-

6-Bromo-3-(1-oxo-5-phenyl-2E,4E-pentadien-1-yl)-2H-1-benzopyran-2-one (3)
Yellow-orange powder; Yield: 54%; Mp: 237°C. 54 was used for visualization and determination of the interaction of compounds with enzyme.
Biological evaluation
Recombinant human CDC25 phosphatases were prepared by previously described method 19 . Assay took place in 96-well plates; buffer solution was adjusted in the following quantities: 50 mM TrisHCl, 50 mM NaCl, 1 mM EDTA, and 0.1% Bovine Serum Albumine, pH 8.1. Incubation period of substrate 3-O-methylfluorescein phosphate with enzyme was 2 h in 30⁰C. Enzyme was exposed to the inhibitors for 20 min and the residual activity of the enzyme has been determined by fluorimetric method.
MALDI/TOFMS
All compounds were dissolved in ethanol at a concentration of 10 -2 M. The solution were then further diluted to 2 · 10 -3 M with ultrapure water. Phosphatases CDC25A was solubilized in Tris A buffer (50 mM Tris, 50 mM NaCl, 1 mM EDTA and 1 mM dithiothreitol [DTT], pH 8.0) at a concentration of 8 · 10 -5 M. One hundred and fifty µl of CDC25A was incubated with 40 µl of compounds for 1 h. Solution was ultracentrifugated on Microcon filter unit with a mass cutoff of 30 kDa (Millipore). The unbound material was eliminated by centrifugation during 10 min at 12,000 rpm and washed three times by 100 µL of ultrapure water. The retentate was then dissolved in 20 µL of ultrapure water. Two µl of the retentate was spotted on the MALDI plate (2 spot for sample in two line) , evaporated to dryness at room temperature. Then one µl of saturated solution of DHB (dihydroxybenzoic acid) was deposited for one of spot and HCCA (α-hydroxycyanocinnamic acid) was deposited for the second spot of each sample on the plate to evaluate the response of each compound with both of matrix, and conserved the spectrum which had the intense response.
The presence of the protonated molecular ion in the MS spectrum is corresponding to a reversible inhibitor activity.
